ABSTRACT
Aim To investigate the gene frequency of UGT1 A1?6 in cancer patients in Anhui Han popula-tion. Methods The 222 cases of blood samples of Han cancer patients were collected from different re-gions of Anhui province, and the UGT1A1?6 geno-types were detected by in situ hybridization fluorescencestaining. Results Patients with a UGT1A1?6 wild type ( GG ) accounted for ( 159 cases, 71. 62％) , which were higher than those of heterozygous mutations ( GA, 52 cases, 23. 42％) and of homozygous muta-tions ( AA, 11 cases, 4. 96％) of the total cases. The mutation rate of UGT1 A1?6 was 16. 67％, and partic-ularly in patients with esophageal cancer it was 43. 75％. The rates of mutation in the patients in Ma ' anshan and Chuzhou were 40. 01％ and 34. 62％, re-spectively, both significantly higher than those of othertumors and regions. Conclusions Cancer patients in Anhui Han population have a high mutant frequency of UGT1 A1?6 . The UGT1 A1?6 genotyping can indi-rectly predict the risk of irinotecan's adverse reaction, which obviously enhances the potentially individualized treatment of irinotecan.
ABSTRACT
<p><b>Objective</b>To evaluate the analgesic effect of intrarectal local anesthesia (IRLA) versus that of periprostatic nerve block anesthesia (PPNB) in initial transrectal ultrasound-guided prostate biopsy (TRUS-PB) for patients with different prostate volumes (PV).</p><p><b>METHODS</b>A total of 253 patients undergoing initial TRUS-PB in our hospital from January 2014 to November 2017 were divided into three PV groups (<50 ml, 50－100 ml, and >100 ml), each again randomized into three subgroups (control, IRLA, and PPNB) with the random number table method. The pain during the procedure was assessed based on the Visual Analogue Scale (VAS) scores and the blind method was used by the biopsy operator, VAS valuator and data analyst.</p><p><b>RESULTS</b>Among the patients with PV <50 ml, the VAS scores in the blank control, IRLA, and PPNB subgroups were 4.39±0.87, 3.51±0.84 and 3.43±1.07, respectively, remarkably higher in the control than in the IRLA and PPNB groups (P<0.05), but with no statistically significant differences between the latter two (P>0.05). Among those with PV of 50－100 ml, the VAS scores in the three subgroups were 4.50±1.05, 4.38±1.13 and 3.38±1.44, respectively, markedly higher in the control and IRLA than in the PPNB group (P<0.05), but with no statistically significant differences between the former two groups (P>0.05). Among those with PV >100 ml, the VAS scores in the three subgroups were 5.19±1.05, 5.00±1.25 and 4.19±0.91, respectively, remarkably higher in the former two groups than in the latter (P<0.05), but with no statistically significant differences between the former two groups (P>0.05).</p><p><b>CONCLUSIONS</b>Either IRLA or PPNB can be recommended for initial TRUS-PB in patients with PV <50 ml, PPNB for those with PV of 50－100 ml, and PPNB with other painkillers for those with PV >100 ml.</p>
Subject(s)
Aged , Humans , Male , Administration, Rectal , Anesthesia, Local , Methods , Anesthetics, Local , Biopsy , Nerve Block , Methods , Pain Measurement , Pain, Procedural , Prospective Studies , Prostate , PathologyABSTRACT
Objective To explore the difference between hemoglobin (HGB) and hematocrit (HCT) results by ABL800 blood gas analyzer and BC5800 blood cell analyzer respectively.Methods ABL800 blood gas analyzer and BC5800 blood cell analyzer were used to detect HGB and HCT in 97 samples of heparin-anticoagulated arterial blood and EDTA-3K anticoagulated versus blood from July 17 to 21,2016 as well as 63 samples of heparin-anticoagulated arterial blood from August 4 to 9,2016.Results Almost all the results by ABL800 blood gas analyzer were higher than those by BC5800 blood cell analyzer.Conclusion There're significant differences between ABL800 blood gas analyzer and traditional way when used to detect HGB and HCT.Blood cell analyzer is the preferred choice to detect HGB and HCT,and the results by the blood gas analyzer can be used for references.
ABSTRACT
Objective To explore the difference between hemoglobin (HGB) and hematocrit (HCT) results by ABL800 blood gas analyzer and BC5800 blood cell analyzer respectively.Methods ABL800 blood gas analyzer and BC5800 blood cell analyzer were used to detect HGB and HCT in 97 samples of heparin-anticoagulated arterial blood and EDTA-3K anticoagulated versus blood from July 17 to 21,2016 as well as 63 samples of heparin-anticoagulated arterial blood from August 4 to 9,2016.Results Almost all the results by ABL800 blood gas analyzer were higher than those by BC5800 blood cell analyzer.Conclusion There're significant differences between ABL800 blood gas analyzer and traditional way when used to detect HGB and HCT.Blood cell analyzer is the preferred choice to detect HGB and HCT,and the results by the blood gas analyzer can be used for references.
ABSTRACT
Some issues about the rationality of subject selection are identified in the registration applications of chemical generic drugs. It should be the sponsor's responsibility to follow the latest information about safety, efficacy and quality control of the proposed drug, and provide a sound basis for subject selection. In this article, issues about the basis of the subject selection of chemical generic drugs are discussed from the aspects of compound, formulation and strength.
ABSTRACT
Objective: To investigate the expression of the reversion-inducing cysteine-rich protein with Kazal motifs (RECK) and matrix metalloproteinase-9(MMP-9) in the prostate carcinoma tissues and to evaluate the role of RECK in the tumorigenesis of prostate carcinoma. Methods: Twenty specimens of prostate cancer and 12 specimens of normal prostate were harvested. RT-PCR and real-time RT-PCR were used to determine the expression of RECK mRNA and RT-PCR was used to determine the expression of MMP-9 mRNA in the specimens. Western blotting analysis was used to determine the expression of RECK protein. Results: It was found that the expression of RECK mRNA in the prostate carcinoma tissues was lower than that in the normal prostate tissues (P<0.01); MMP-9 expression in the prostate carcinoma tissues was significantly higher than that of the normal prostate tissues (P<0.01). Western blotting analysis showed that the expression of RECK protein in the carcinoma tissues was lower than that in the normal prostate tissue (P<0.01). Conclusion: RECK gene expression is lower in the prostate carcinoma tissues; RECK may inhibit the progression and metastasis of cancer through inhibiting MMP-9 expression.
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the regulatory effect of the nonsteroidal anti-inflammatory drug NS398 on the expression of the RECK gene in the animal model of prostate cancer.</p><p><b>METHODS</b>Nude mouse models of prostate cancer were divided into an experimental and a control group, the former fed with NS398 at 0.1 mg/g per day for 10, 20 and 30 days, while latter left without medication. All the mice were killed at 30 days, the mRNA expressions of RECK and MMP-9 in the tumor tissues measured by RT-PCR, and the protein level of RECK evaluated by Western blot.</p><p><b>RESULTS</b>Both the mRNA and protein expressions of RECK were increased, while the level of MMP-9 decreased, in an obviously time-dependent manner in the experimental group as compared with the control.</p><p><b>CONCLUSION</b>NS398 obviously inhibits the pathogenesis and metastasis of prostate cancer, which may be attributed to its induction of the expression of the RECK gene and suppression of the expression of MMP-9.</p>
Subject(s)
Animals , Humans , Male , Mice , Anti-Inflammatory Agents, Non-Steroidal , Pharmacology , GPI-Linked Proteins , Metabolism , Gene Expression Regulation , Matrix Metalloproteinase 9 , Metabolism , Mice, Nude , Nitrobenzenes , Pharmacology , Sulfonamides , Pharmacology , Tumor Cells, CulturedABSTRACT
<p><b>OBJECTIVES</b>To investigate the regulative effect of the nonsteroidal anti-inflammatory drug NS398 on the RECK gene in the prostate carcinoma strain DU145.</p><p><b>METHODS</b>DU145 was treated with various concentrations of NS398 for 48 hours. The mRNA level was measured by RT PCR technique and the expression of the RECK protein determined by Western blot.</p><p><b>RESULTS</b>The mRNA level of the RECK gene was obviously higher, while the MMP9 level markedly lower in the treated group than in the control, and so was the expression of the RECK protein.</p><p><b>CONCLUSION</b>NS398 induces the expression of the RECK gene, which might be the mechanism of its anti-tumor effect.</p>
Subject(s)
Animals , Cattle , Humans , Male , Anti-Inflammatory Agents, Non-Steroidal , Pharmacology , Blotting, Western , Cell Line, Tumor , GPI-Linked Proteins , Gene Expression Regulation, Neoplastic , Membrane Glycoproteins , Genetics , Nitrobenzenes , Pharmacology , Prostatic Neoplasms , Genetics , Metabolism , Pathology , RNA, Messenger , Genetics , Metabolism , Reverse Transcriptase Polymerase Chain Reaction , Sulfonamides , PharmacologyABSTRACT
<p><b>OBJECTIVE</b>To investigate the expression and significance of RECK gene and MMP-9 in prostate cell strains such as BPH-1, DU45, LNCaP and PC-3.</p><p><b>METHODS</b>The expression of mRNA of RECK and MMP-9 was measured by RT-PCR and RECK protein was evaluated by Western blot.</p><p><b>RESULTS</b>The mRNA level of the RECK gene in the prostate carcinoma cell strains, such as DU45, LNCaP and PC-3, was lower than that in the benign prostate hyperplasia cell line BPH-1, while MMP-9 had a higher expression. The protein level of RECK in DU-45, LNCaP and PC-3 was lower than that in the BPH-1.</p><p><b>CONCLUSION</b>The RECK gene is supposed to be a kind of tumor suppressor gene, which may act by inhibiting the activity of MMP-9.</p>